Skip to main content
. Author manuscript; available in PMC: 2018 Aug 15.
Published in final edited form as: Int J Cancer. 2017 May 26;141(4):711–720. doi: 10.1002/ijc.30782

Figure 1.

Figure 1

Frequency distribution and box plot of time intervals from study entry to diagnosis of 262 newly-developed HCC cases by serum levels of AFB1-albumin adducts at study entry. (A) Distribution of time intervals from study entry to HCC diagnosis in cases with high or low/undetectable serum AFB1-albumin adduct levels (p<0.0001). (B) Box plot of time intervals (means ± SD) from study entry to HCC diagnosis in cases with high (7.5±5.6) and low/undetectable (10.9±4.5) serum levels of AFB1-albumin adducts (p<0.0001). In the box plot, the filled circles indicate the outliers lying outside the 10th and 90th percentiles.